Prostate Cancer and Primary Care

Prostate Cancer and Primary Care

The Prostate Cancer and Primary Care module will help providers understand the differing interpretation of evidence relevant to early detection of prostate cancer and related possible benefit and harms. This module will also provide the most recent literature and statistics surrounding prostate cancer screening and a brief overview of the latest treatment options available to men. In addition, this module will provide information of identification of patients at increased risk and demonstrate the role that providers' personal and professional values and their patients' values play in assessing the balance of benefit and harms from PSA testing. Lastly, through case studies the module will demonstrate how to engage patients in an effective shared decision making process if providers choose to offer their patients an opportunity to participate in a challenging healthcare decision. The illustration will include how to utilize the prostate cancer screening shared decision making tools and provide ideas for practice workflow.

Course sections include:
Early Detection of Prostate Cancer with PSA (Video & Slides)
Developments in Managing the Prostate Cancer Continuum (Video & Slides)
Shared Decision Making (Video & Slides)
Tools & Resources

Learning Objectives

  • Examine the evidence on the effectiveness of screening for prostate cancer with PSA and opportunities to reduce overtreatment of screen-detected cancer with its attendant harms.
  • Evaluate how different interpretations of this evidence and these opportunities for harm reduction lead clinicians to different conclusions about the wisdom of offering PSA testing to patients today.
  • Summarize the clinical guidelines on screening for prostate cancer developed by national organizations and by a multi-stakeholder panel of Massachusetts patients, providers, insurers, and public health officials.
  • Describe the role of shared decision making involving patients and providers to assure that any decision about PSA testing truly reflects patients' informed consent and their value.
  • Review the potential for evolving approaches incorporating recently developed diagnostic and prognostic markers to reduce the risks of screening and treatment.

Faculty

Roger Luckmann, MD, MPH
Associate Professor of Family Medicine and Community Health, University of Massachusetts Medical School

Roger Luckmann, MD, MPH, Associate Professor of Family Medicine and Community Health at UMass Medical School and a primary care provider.  His research on prostate, breast, colon and lung cancer screening has been supported by the National Cancer Institute, the Centers for Disease Control and Prevention, and the Patient Outcomes Research Institute. Recently he led a project in Massachusetts that convened a multi-stakeholder panel to develop a state guideline on prostate cancer screening with PSA.

Mark Kennedy, MBA
Executive Director, Massachusetts Prostate Cancer Coalition (MPCC)

Mark Kennedy is the Executive Director of the Massachusetts Prostate Cancer Coalition (MPCC). Kennedy, a recognized leader in prostate cancer education and advocacy, has been instrumental in driving effective multidisciplinary prostate cancer programs and interventions at local, state and national levels. As executive director, Kennedy aims to position MPCC as the premier source of information and education for prostate cancer health in Massachusetts.

Kennedy previously served as Manager of Men's Health Programs for Dana-Farber's Community Benefits Office. Working with healthcare providers, he delivered prostate cancer educational interventions and is developing prostate cancer clinical practice guidance to standardize service protocols for high risk men.  Kennedy's work led to the creation and delivery of an award-winning evidence-based prostate cancer education protocol, which he used to manage Dana-Farber's Blum Community Prostate Cancer Education and Screening Program.  Currently, Kennedy serves as Co-chair of the Massachusetts Department of Public Health Comprehensive Cancer Program, Prostate Cancer Workgroup.

Course Fees : Free

Format: Slides & Video

CME Credit: 1 AMA PRA Category 1 Credit™ , risk management study

The Massachusetts Medical Society designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only credit commensurate with the extent of their participation in the activity.

The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Activity Term
Start: November 1, 2015    
End: November 30, 2017   

System requirements:

Desktops/Laptops
Windows, XP, Vista, 7, 8
Mac OSX 10.6 higher

Most modern browsers including:
IE8,9,10
Firefox 18.0+
Chrome 26+
Safari 5+

Flash player is required for some Online CME courses.

Mobile/Tablet
iOS devices beginning with OS version 5 or higher (includes, iPhone, ipad and iTouch devices)

Android devices including tablets and phones.
Windows RT and tablets on Windows 8 are also supported.

When you click "Purchase," your Order Total on the next screen will be $0.

 


FacebookTwitterLinkedInYouTube

Copyright © 2017. Massachusetts Medical Society, 860 Winter Street, Waltham Woods Corporate Center, Waltham, MA 02451-1411

(781) 893-4610 | (781) 893-3800 | Member Information Hotline: (800) 322-2303 x7311